GO:0045322 unmethylated CpG binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045322 (unmethylated CpG binding) describes the molecular function of selectively binding DNA at unmethylated CpG dinucleotides, which are frequently enriched at gene promoters.
• Proteins that read unmethylated CpG motifs include CXXC5, KAT6A, CDCA7, and MBD1, each using distinct structural domains to recognize CpG dinucleotides in different DNA contexts.
• Unmethylated CpG binding is central to epigenetic regulation, linking DNA methylation status to transcriptional activation, chromatin modification, and cellular proliferation.
• Dysregulation of unmethylated CpG binding proteins is implicated in cancer, immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome, and other diseases.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of unmethylated CpG binding proteins in health and disease.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to accelerate research on unmethylated CpG binding and its downstream pathways.
Description
GO:0045322, unmethylated CpG binding, is a molecular function defined by the selective binding to unmethylated CpG dinucleotides, which are often associated with gene promoters. This function is critical for interpreting the epigenetic information encoded by DNA methylation, a major regulator of gene expression. Proteins that bind unmethylated CpG motifs act as readers of the epigenome, translating the absence of methylation into transcriptional and chromatin-modifying outcomes. Research on unmethylated CpG binding has revealed diverse protein families, including CXXC domain proteins such as CXXC5, winged helix domain proteins like KAT6A, and the unique DNA-binding domain of CDCA7. These proteins are involved in estrogen-mediated proliferation, histone acetylation, and non-B DNA recognition, respectively. Understanding their mechanisms provides insight into development, cancer, and immune disorders. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of unmethylated CpG binding, covering its definition, mechanisms, key genes, disease links, and experimental approaches including CRISPR-based models.
unmethylated CpG binding At A Glance
| GO ID | GO:0045322 |
|---|---|
| GO term | unmethylated CpG binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to an unmethylated CpG motif. Unmethylated CpG dinucleotides are often associated with gene promoters. |
| Major function | Selective recognition of unmethylated CpG dinucleotides in DNA, often at gene promoters, to regulate transcription and chromatin state. |
| Representative proteins | CXXC5, KAT6A, CDCA7, MBD1 (via its CXXC domain) |
| Related processes | Epigenetic regulation, transcriptional activation, histone modification, cellular proliferation |
| Disease relevance | Cancer, ICF syndrome, immune disorders |
What Is GO:0045322?
Unmethylated CpG binding (GO:0045322) is the molecular function of binding to a DNA sequence containing an unmethylated CpG dinucleotide, where a cytosine nucleotide is followed by a guanine nucleotide and the cytosine is not methylated. Unmethylated CpG dinucleotides are frequently found in gene promoters and are associated with active or poised transcription. This binding function is distinct from methyl-CpG binding, which recognizes methylated CpG dinucleotides and typically mediates transcriptional repression.
Why Is unmethylated CpG binding Important in Cell Biology?
Unmethylated CpG binding is important because it allows cells to read the DNA methylation landscape and convert it into functional outcomes such as gene activation or chromatin remodeling. This function is essential for normal development, cell identity, and proliferation, and its disruption contributes to diseases including cancer and immunodeficiency syndromes.
• Enables interpretation of DNA methylation patterns, a core epigenetic mechanism.
• Regulates gene promoters that are enriched in unmethylated CpG dinucleotides.
• Links to transcriptional activation and histone acetylation via proteins like KAT6A.
• Contributes to estrogen-mediated cellular proliferation through CXXC5.
• Involved in non-B DNA recognition and genome stability via CDCA7.
• Dysregulation is associated with cancer and ICF syndrome.
• Provides targets for epigenetic therapies and biomarker development.
• Essential for understanding the interplay between DNA methylation and chromatin.
• Facilitates research on immune responses to bacterial DNA via TLR9, which recognizes unmethylated CpG motifs.
• Supports the development of CRISPR models to study causal roles of CpG-binding proteins.
Molecular Mechanism of unmethylated CpG binding
Recognition of unmethylated CpG dinucleotides
In simple terms: Proteins scan DNA and bind specifically to CpG sites that lack methylation.
Unmethylated CpG binding proteins use specialized domains to recognize CpG dinucleotides in the context of unmethylated DNA. For example, the CXXC domain of CXXC5 selectively binds unmethylated CpG dinucleotides, contributing to estrogen-mediated cellular proliferation. Similarly, the winged helix domain of KAT6A is recruited to unmethylated CpG islands, enabling histone acetylation. CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA structure. These examples illustrate the structural diversity underlying this function.
Structural basis of CpG recognition
In simple terms: Different proteins use different shapes to grab unmethylated CpG DNA.
Structural studies have revealed that CXXC domains coordinate with unmethylated CpG dinucleotides through specific hydrogen bonds and van der Waals interactions. The winged helix domain of KAT6A inserts into the DNA major groove to read unmethylated CpG islands. CDCA7 uses a unique domain to recognize a CpG dyad within a non-B DNA context, expanding the repertoire of CpG recognition beyond canonical B-DNA. These structural insights explain how proteins achieve specificity for unmethylated over methylated CpG.
Downstream effects on transcription and chromatin
In simple terms: Once bound, these proteins can turn genes on or modify chromatin.
Binding of unmethylated CpG motifs often leads to recruitment of transcriptional coactivators or chromatin-modifying enzymes. KAT6A, upon binding unmethylated CpG islands, acetylates histones to promote gene expression. CXXC5 binding to unmethylated CpG dinucleotides contributes to estrogen-mediated proliferation, likely by modulating transcription. In contrast, methyl-CpG-binding domain proteins such as MBD1 bind methylated CpG and typically repress transcription, highlighting the opposing roles of methylated versus unmethylated CpG readers.
Regulation and cofactors
In simple terms: Other molecules can help or hinder these proteins from binding CpG DNA.
The binding of unmethylated CpG motifs can be regulated by the availability of cofactors, post-translational modifications, and the local chromatin environment. For instance, the histone acetyltransferase activity of KAT6A is dependent on its recruitment to unmethylated CpG islands via its DNA binding winged helix domain. CXXC5 function is linked to estrogen signaling, suggesting hormonal regulation. CDCA7's recognition of non-B DNA may be influenced by DNA topology and supercoiling. Additionally, the Toll-like receptor 9 (TLR9) recognizes unmethylated CpG motifs in bacterial DNA, triggering immune responses, which underscores the broader biological context of CpG recognition.
Key Genes Involved in GO:0045322 unmethylated CpG binding
The following genes encode proteins that bind unmethylated CpG dinucleotides or are directly involved in this molecular function, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXXC5 | Binds unmethylated CpG dinucleotides via its CXXC domain; contributes to estrogen-mediated cellular proliferation | Cancer, estrogen signaling, cell proliferation |
| KAT6A | Histone acetyltransferase recruited to unmethylated CpG islands via a winged helix domain; acetylates histones | Epigenetics, transcriptional regulation, cancer |
| CDCA7 | Harbors a unique DNA binding domain that recognizes a CpG dyad in non-B DNA; involved in ICF syndrome | ICF syndrome, genome stability, non-B DNA |
| MBD1 | Methyl-CpG-binding domain protein 1; contains a CXXC domain that binds unmethylated CpG, in addition to methyl-CpG binding | Epigenetic regulation, transcriptional repression, cancer |
| TLR9 | Toll-like receptor 9 recognizes unmethylated CpG motifs in bacterial DNA, triggering innate immune responses | Immunology, vaccine adjuvants, autoimmune diseases |
| MBD2 | Methyl-CpG-binding domain protein 2; binds methylated CpG, but its study informs unmethylated CpG binding contrasts | Epigenetics, transcriptional repression |
| MBD3 | Methyl-CpG-binding domain protein 3; component of NuRD complex, involved in chromatin remodeling | Chromatin remodeling, development |
| MBD4 | Methyl-CpG-binding domain protein 4; involved in DNA repair at methylated CpG sites | DNA repair, cancer |
| MeCP2 | Methyl-CpG-binding protein 2; binds methylated CpG, mutations cause Rett syndrome | Neurodevelopment, Rett syndrome |
| KDM2A | Contains a CXXC domain that binds unmethylated CpG; histone demethylase | Epigenetics, transcription |
| KDM2B | Contains a CXXC domain that binds unmethylated CpG; histone demethylase | Epigenetics, development |
| CXXC1 | Contains a CXXC domain that binds unmethylated CpG; component of SET1 complex | Epigenetics, transcription |
| DNMT1 | DNA methyltransferase 1; maintains methylation, indirectly affecting unmethylated CpG availability | DNA methylation, epigenetics |
| DNMT3A | DNA methyltransferase 3A; de novo methylation, influencing unmethylated CpG landscapes | DNA methylation, development |
| DNMT3B | DNA methyltransferase 3B; de novo methylation, influencing unmethylated CpG landscapes | DNA methylation, ICF syndrome |
| TET1 | Ten-eleven translocation 1; oxidizes methylcytosine, generating unmethylated CpG | DNA demethylation, epigenetics |
| TET2 | Ten-eleven translocation 2; oxidizes methylcytosine, generating unmethylated CpG | DNA demethylation, cancer |
| UHRF1 | Ubiquitin-like with PHD and RING finger domains 1; binds hemimethylated DNA, influencing CpG methylation | DNA methylation, epigenetics |
How Is unmethylated CpG binding Regulated?
The binding of unmethylated CpG motifs is regulated at multiple levels. DNA methylation itself is a primary determinant: the presence of 5-methylcytosine at CpG dinucleotides prevents binding by unmethylated CpG-specific proteins while promoting binding by methyl-CpG-binding domain proteins. Enzymes such as DNMTs and TET proteins dynamically modulate the methylation status of CpG sites, thereby controlling the availability of unmethylated CpG motifs. Additionally, post-translational modifications and interacting partners can influence the affinity and specificity of CpG-binding proteins. For example, CXXC5 function is linked to estrogen signaling, suggesting hormonal regulation. The recruitment of KAT6A to unmethylated CpG islands is essential for its histone acetyltransferase activity, and this recruitment may be regulated by cellular signals. CDCA7's recognition of non-B DNA may be influenced by DNA topology and supercoiling. Overall, the regulation of unmethylated CpG binding is tightly coupled to the dynamic epigenetic state of the cell.
unmethylated CpG binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXXC5 | Cancer, estrogen-mediated proliferation | Knockout or overexpression in breast cancer cell lines |
| KAT6A | Cancer, epigenetic dysregulation | Knockout and point mutation models in leukemia cell lines |
| CDCA7 | ICF syndrome, genome instability | Knock-in of patient mutations in cell lines |
| MBD1 | Cancer, epigenetic regulation | Knockout and overexpression in cancer cell lines |
| TLR9 | Autoimmune diseases, immune response | Knockout in immune cell lines and primary cells |
Cancer
Unmethylated CpG binding proteins are frequently dysregulated in cancer. CXXC5 contributes to estrogen-mediated cellular proliferation, and its aberrant expression may promote tumor growth in hormone-responsive cancers. KAT6A is a histone acetyltransferase recruited to unmethylated CpG islands; its dysregulation can lead to altered gene expression programs that drive oncogenesis. MBD1, which contains a CXXC domain that binds unmethylated CpG, is involved in epigenetic regulation and has been implicated in cancer progression. These findings suggest that targeting unmethylated CpG binding proteins could offer therapeutic opportunities.
ICF syndrome
Immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome is a rare autosomal recessive disorder caused by mutations in genes involved in DNA methylation, including DNMT3B and CDCA7. CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of non-B DNA, and mutations in CDCA7 lead to ICF syndrome. This highlights the critical role of proper CpG recognition in genome stability and immune function.
Immune disorders
Toll-like receptor 9 (TLR9) recognizes unmethylated CpG motifs in bacterial DNA, triggering innate immune responses. Dysregulation of TLR9 signaling can contribute to autoimmune diseases such as systemic lupus erythematosus, where self-DNA containing unmethylated CpG motifs may activate TLR9 and drive inflammation. Understanding the molecular basis of unmethylated CpG recognition by TLR9 is therefore relevant for developing therapies for immune disorders.
From unmethylated CpG binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CXXC5 affect estrogen-mediated proliferation? | CXXC5 knockout in estrogen-responsive cancer cell lines |
| How does KAT6A recognize unmethylated CpG islands? | KAT6A point mutations in the winged helix domain |
| What is the impact of CDCA7 mutations on non-B DNA binding? | CDCA7 knock-in of ICF-associated mutations |
| Can MBD1 CXXC domain be tagged to track unmethylated CpG binding? | Tagged knock-in of MBD1 with fluorescent protein |
| Does overexpression of CXXC5 drive proliferation? | CXXC5 overexpression in cell lines |
| What are the downstream targets of KAT6A at unmethylated CpG islands? | KAT6A knockout followed by RNA-seq and ChIP-seq |
How to Study the unmethylated CpG binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EMSA | Protein-DNA binding affinity and specificity | Characterizing CXXC5 binding to unmethylated CpG |
| SPR | Real-time binding kinetics | Quantifying KAT6A-DNA interactions |
| ChIP-seq | Genome-wide binding sites | Mapping KAT6A and CXXC5 occupancy |
| MBD-fused luciferase assay | CpG methylation levels | Detecting unmethylated CpG availability |
| CRISPR knockout screens | Gene essentiality and pathway components | Identifying regulators of CpG binding |
| RNA-seq | Transcriptional changes | Assessing downstream effects of CpG binding protein loss |
| Proteomics | Protein interactions and modifications | Identifying cofactors of CpG-binding proteins |
| Structural biology (crystallography/cryo-EM) | 3D structures of protein-DNA complexes | Understanding CpG recognition mechanisms |
DNA binding assays
Electrophoretic mobility shift assays (EMSA) and surface plasmon resonance (SPR) can measure the binding affinity of proteins to unmethylated CpG oligonucleotides. These methods are used to characterize the specificity of CXXC5, KAT6A, and CDCA7 for unmethylated versus methylated CpG.
Methyl-CpG-binding domain-fused luciferase detection
A hybridization-based CpG methylation level detection using methyl-CpG-binding domain-fused luciferase has been developed to quantify methylation levels, which indirectly informs on unmethylated CpG availability. This method can be adapted to study unmethylated CpG binding proteins.
Chromatin immunoprecipitation (ChIP)
ChIP followed by sequencing (ChIP-seq) can map the genomic binding sites of unmethylated CpG binding proteins such as KAT6A and CXXC5, revealing their target promoters and enhancers.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes required for unmethylated CpG binding-dependent processes, such as proliferation or survival. These screens are powerful for discovering novel components of the pathway.
How CRISPR Can Be Used to Study GO:0045322 unmethylated CpG binding
Knockout
CRISPR knockout of genes encoding unmethylated CpG binding proteins, such as CXXC5, KAT6A, or CDCA7, allows researchers to assess their loss-of-function phenotypes. For example, CXXC5 knockout can reduce estrogen-mediated proliferation, while KAT6A knockout affects histone acetylation and gene expression. CDCA7 knockout can model ICF syndrome-associated defects.
Point Mutation
Introducing point mutations in the DNA-binding domains of unmethylated CpG binding proteins can dissect the specific residues required for CpG recognition. For instance, mutations in the CXXC domain of CXXC5 or the winged helix domain of KAT6A can abolish unmethylated CpG binding without affecting other functions.
Knock-in
Knock-in of disease-associated mutations, such as those found in CDCA7 in ICF syndrome, can create isogenic models to study the impact of these mutations on CpG binding and genome stability. Additionally, knock-in of epitope tags or fluorescent proteins enables tracking of endogenous proteins.
Overexpression
Overexpression of unmethylated CpG binding proteins like CXXC5 can drive cellular proliferation and transformation, providing a gain-of-function model to study oncogenic roles. Overexpression of KAT6A can enhance histone acetylation at target genes.
How EDITGENE Supports unmethylated CpG binding Research
Researchers studying unmethylated CpG binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as proliferation, epigenetic regulation, or disease development. CRISPR-based cell models provide a robust way to establish causality by precisely manipulating the genome.
Contact EDITGENE today to design your custom CRISPR model for unmethylated CpG binding research.
Frequently Asked Questions About unmethylated CpG binding
What is unmethylated CpG binding?
Unmethylated CpG binding (GO:0045322) is the molecular function of selectively binding to DNA sequences containing an unmethylated CpG dinucleotide, which are often found in gene promoters.
What genes are involved in unmethylated CpG binding?
Key genes include CXXC5, KAT6A, CDCA7, and MBD1, which encode proteins with domains that recognize unmethylated CpG dinucleotides.
How does unmethylated CpG binding differ from methyl-CpG binding?
Unmethylated CpG binding recognizes CpG dinucleotides that lack methylation, often leading to transcriptional activation, whereas methyl-CpG binding recognizes methylated CpG and typically mediates transcriptional repression.
What diseases are associated with unmethylated CpG binding proteins?
Dysregulation of these proteins is linked to cancer, ICF syndrome, and immune disorders such as autoimmunity.
What is the role of CXXC5 in unmethylated CpG binding?
CXXC5 binds unmethylated CpG dinucleotides via its CXXC domain and contributes to estrogen-mediated cellular proliferation.
How does KAT6A recognize unmethylated CpG islands?
KAT6A is recruited to unmethylated CpG islands through a DNA binding winged helix domain, which enables its histone acetyltransferase activity.
What is CDCA7's function in CpG recognition?
CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of non-B DNA, and mutations in CDCA7 cause ICF syndrome.
Can CRISPR be used to study unmethylated CpG binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of genes involved in unmethylated CpG binding and their downstream effects.
What methods are used to study unmethylated CpG binding?
Common methods include EMSA, SPR, ChIP-seq, MBD-fused luciferase assays, and CRISPR screens.
Why is unmethylated CpG binding important for gene regulation?
It allows cells to read the DNA methylation landscape and convert it into transcriptional outcomes, often activating genes with unmethylated CpG promoters.
Conclusion
Unmethylated CpG binding (GO:0045322) is a fundamental molecular function that enables proteins to interpret the epigenetic state of CpG dinucleotides, which are frequently located at gene promoters. Through diverse structural domains, proteins such as CXXC5, KAT6A, CDCA7, and MBD1 recognize unmethylated CpG motifs and regulate transcription, chromatin modification, and cellular proliferation. Dysregulation of these proteins is implicated in cancer, ICF syndrome, and immune disorders, making them attractive targets for therapeutic intervention. CRISPR-based cell models, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to establish causal roles and dissect mechanisms. EDITGENE offers comprehensive services to generate these models and support bioinformatics analysis, empowering researchers to advance the field of unmethylated CpG binding and its disease relevance.
References
- 1. Ayaz G et al.. 2020. CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.. Sci Rep 10(1):5971 PMID: 32249801
- 2. Weber LM et al.. 2023. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.. Nucleic Acids Res 51(2):574-594 PMID: 36537216
- 3. Vinson C et al.. 2012. CG methylation.. Epigenomics 4(6):655-63 PMID: 23244310
- 4. Hardikar S et al.. 2024. The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA.. Sci Adv 10(34):eadr0036 PMID: 39178265
- 5. Hemmi H et al.. 2000. A Toll-like receptor recognizes bacterial DNA.. Nature 408(6813):740-5 PMID: 11130078
- 6. Du Q et al.. 2015. Methyl-CpG-binding domain proteins: readers of the epigenome.. Epigenomics 7(6):1051-73 PMID: 25927341
- 7. Goto A et al.. 2023. Hybridization-based CpG methylation level detection using methyl-CpG-binding domain-fused luciferase.. Anal Bioanal Chem 415(12):2329-2337 PMID: 36961575
- 8. Li L et al.. 2015. An epigenetic regulator: methyl-CpG-binding domain protein 1 (MBD1).. Int J Mol Sci 16(3):5125-40 PMID: 25751725
